We found that MG + anti-VEGF therapy significantly reduced the expression and distribution of F4/80, Iba-1, and GFAP in the retina and had a certain inhibitory effect on the activation of inflammatory cells. The gene discussed is AIF1; the disease is myasthenia gravis.